SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 1, 2015, Pages 58-64

  Budd, George T ^a   Barlow, William E ^c   Moore, Halle C F ^a   Hobday, Timothy J ^f   Stewart, James A ^g   Isaacs, Claudine ^h   Salim, Muhammad ⁱ   Cho, Jonathan K ^j   Rinn, Kristine J ^d   Albain, Kathy S ^k   Chew, Helen K ^l   Burton, Gary V ^m   Moore, Timothy D ^b   Srkalovic, Gordan ⁿ   McGregor, Bradley A ^p   Flaherty, Lawrence E ^o   Livingston, Robert B ^r   Lew, Danika L ^c   Gralow, Julie R ^e   Hortobagyi, Gabriel N ^q  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Mid Ohio Oncology Group   (United States)

^c SWOG STATISTICAL CENTER   (United States)

^d SWEDISH MEDICAL CENTER   (United States)

^e SEATTLE CANCER CARE ALLIANCE   (United States)

^f MAYO CLINIC   (United States)

^g BAYSTATE MEDICAL CENTER   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ Allan Blair Cancer Centre   (Canada)

^j UNIVERSITY OF HAWAII   (United States)

^k LOYOLA UNIVERSITY CHICAGO   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m LOUISIANA STATE UNIVERSITY   (United States)

ⁿ Department of Medical Oncology and Hematology   (United States)

^o WAYNE STATE UNIVERSITY   (United States)

^p Willford Hall Medical Center ^*  (United States)

^q UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^r UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FILGRASTIM; GAMMA UROGASTRONE; HEMOGLOBIN; PACLITAXEL;

ARTICLE; BREAST CANCER; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; EARLY CANCER; FEBRILE NEUTROPENIA; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOCYTE; LEUKOPENIA; LOCAL THERAPY; LOG RANK TEST; MUSCULOSKELETAL PAIN; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZATION; SKIN DISEASE; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CANCER STAGING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PACLITAXEL; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84920576208     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.3296     Document Type: Article

References (16)

1. Joensuu H, Kellokumpu-Lehtinen PL, Huovi-nen R, et al.: Adjuvant capecitabine, docetaxel, cy-clophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. J Clin Oncol 30:11-18, 2011
2. Muss HB, Berry DA, Cirrincione C.T., et al.: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055-2065, 2009
3. Swain SM, Tang G, Geyer CE Jr, et al.: Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: The NSABP B-38 trial. J Clin Oncol 31:3197-3204, 2013
4. Citron ML, Berry DA, Cirrincione C, et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
5. Sparano JA, Wang M, Martino S., et al.: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
6. Ellis GK, Livingston RB, Gralow J.R., et al.: Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 20:3637-3643, 2002
7. Ellis GK, Barlow WE, Gralow J.R., et al.: Phase III comparison of standard doxorubicin and cyclo-phosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 29:1014-1021, 2011
8. Paik S, Shak S, Tang G., et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
9. Shulman LN, Cirrincione CT, Berry D.A., et al.: Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol 30:4071-4076, 2012
10. Demets DL: Group sequential procedures: Calendar versus information time. Stat Med 8:1191-1198, 1989
11. Von Hoff DD, Layard MW, Basa P, et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
12. Chlebowski RT, Paroly WS, Pugh R.P., et al.: Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64:47-51, 1980
13. Paik S, Tang G, Shak S., et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
14. Albain KS, Barlow WE, Shak S, et al.: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
15. Sucheston LE, Zhao H, Yao S., et al.: Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 130:993-1002, 2011
16. Yao S, Sucheston LE, Zhao H, et al.: Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-247, 2014